Cardica Updates Enrollment Progress In European Clinical Trial

        Cardica Updates Enrollment Progress In European Clinical Trial

PR Newswire

REDWOOD CITY, Calif., Feb. 27, 2013

REDWOOD CITY, Calif., Feb. 27, 2013 /PRNewswire/ -- Cardica, Inc. (Nasdaq:
CRDC) today announced that 109 patients have been enrolled in the company's
European clinical trial designed to evaluate the safety of its MicroCutter
XCHANGE™ 30 cutting/stapling device in a variety of surgical procedures.
Cardica plans to complete enrollment of 160 patients for the European clinical
trial in the second calendar quarter of 2013.

"We are making progress with the MicroCutter XCHANGE 30 in Europe," said
Bernard A. Hausen, M.D., Ph.D., president and chief executive officer of
Cardica. "In the last four weeks, we have enrolled an additional 19 patients
in our clinical trial, with more scheduled in the days ahead. And, we continue
to gain valuable feedback from European surgeons deploying the device in a
variety of procedures, to prepare the device for broader distribution in the
near future. To date the MicroCutter XCHANGE 30 device has been used in over
280 procedures and deployed more than 800 times."

AboutCardica

Cardicadesigns and manufactures proprietary stapling and anastomotic devices
for cardiac and laparoscopic surgical procedures.Cardica's technology
portfolio is intended to minimize operating time and enable minimally-invasive
and robot-assisted surgeries. Cardica manufactures and markets its automated
anastomosis systems, the C-Port^® Distal Anastomosis Systems and PAS-Port^®
Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery,
and has shipped over 44,100 units throughout the world. In
addition,Cardicais developing the Cardica^® MicroCutter XCHANGE™ 30, a
cartridge-based microcutter device with a five-millimeter shaft diameter, and
the Cardica^® MicroCutter XPRESS™ 30, a true multi-fire laparoscopic stapling
device. Both MicroCutter devices are designed to be used in a variety of
procedures, including bariatric, colorectal, thoracic and general surgery. The
Cardica MicroCutter XCHANGE 30 and XPRESS 30 products require 510(k) review
and are not yet commercially available in the U.S.

Forward-Looking Statements

The statement in this press release regarding Cardica's plans to complete
enrollment in the European clinical trial in the second quarter of calendar
year 2013, is a "forward-looking statement." There are a number of important
factors that could cause Cardica's results to differ materially from those
indicated by this forward-looking statement, including: that the XCHANGE 30
may face development, regulatory and manufacturing risks; that surgeons may
not use the XCHANGE 30 correctly, which could cause unfavorable results that
may impair the acceptance of the XCHANGE 30 by other surgeons or otherwise
delay completion of enrollment; and that Cardica may not have sufficient funds
to complete enrollment in the clinical trial, as well as other risks detailed
from time to time in Cardica's reports filed with the U.S. Securities and
Exchange Commission, including its Current Report on Form 10-Q for the quarter
endedDecember 31, 2012. Cardica expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein. You are encouraged to read
Cardica's reports filed with the U.S. Securities and Exchange Commission,
available at www.sec.gov.

SOURCE Cardica, Inc.

Website: http://www.cardica.com
Contact: Bob Newell, Vice President, Finance and Chief Financial Officer,
+1-650-331-7133, investors@cardica.com
 
Press spacebar to pause and continue. Press esc to stop.